Table 3 Tumor responses
|  | All patients (N = 19) | Group by administration schedule of MASCT-I | Group by disease subtype | ||
|---|---|---|---|---|---|
Schedule-I group (N = 9) | Schedule-II group (N = 10) | Soft-tissue sarcoma (N = 13) | Bone sarcoma (N = 6) | ||
Best overall response | |||||
 Partial response | 6 (31.6%) | 3 (33.3%) | 3 (30.0%) | 4 (30.8%) | 2 (33.3%) |
 Stable disease | 7 (36.8%) | 1 (11.1%) | 6 (60.0%) | 6 (46.2%) | 1 (16.7%) |
 Progressive disease | 6 (31.6%) | 5 (55.6%) | 1 (10.0%) | 3 (23.1%) | 3 (50.0%) |
Objective response rate | 31.6% (12.6–56.6) | 33.3% (7.5–70.1) | 30.0% (6.7–65.3) | 30.8% (9.1–61.4) | 33.3% (4.3–77.7) |
Disease control rate | 68.4% (43.5–87.4) | 44.4% (29.9–92.5) | 90.0% (69.2–100.0) | 76.9% (46.2–95.0) | 50.0% (11.8–88.2) |